The Expora Platform™
The Expora Platform™ unlocks an innovative new type of extracellular vesicle (EV) immunotherapy
Synthetic Biology Platform
Scalable Manufacturing
The Expora Platform™ unlocks potential for large commercial scale EV manufacturing through homogenous producer cells, selective multimode purification, and stringent quality controls. Our cost-effective processes have potential to scale to produce tens of millions of doses per year, with unmatched consistency.
Precision Medicine by Design
Expora's gut-targeted, multi-specific EVs are the ideal modality to treat immune-mediated GI diseases, where conventional modalities face safety, efficacy, or delivery limitations. Our modular EV design begins with a chassis targeting fundamental immune processes underpinning numerous GI diseases, upon which designer therapeutic cargo (e.g., antibodies) can be loaded without sacrificing manufacturing consistency to target clinically-validated pathways.
